[Adults] Global Enterprises Helping Drive Biotechs Such as N_u_v_i_l_e_x (N.V.L.X) Higher

[New Report]

International
Enterprises Helping Drive
Biotechs Such as Nuvilex
(N-V-L-X) Higher

Are you overlooking the trend?

The N a s d a q Biotechnology Index has
fundamentally doubled the
returns of the benchmark S&P 5-0-0 index in the
first six months of this year with
rewards about thirty percent.
Over-seas, biotech is just as popping.  Half of the
top ten biggest increases of Japan’s
J A S D A Q index are biotechnology stocks.
Japan’s Prime Minister Shinzo Abe’s Cabinet is
anticipated to bring
revisions of the
Pharmaceutical Affairs Law to the country’s Parliament on June
27th to continue to change the
country’s laws to expedite biotechnology r
& d initiatives of the country.  The United
States  passed the “FDAs Safety and Innovation Act” into law last
July, signaling the country’s
energies to accelerate
the rate to market of novel d-r-u-g-s that
join areas of a-bundant unmet
medical need.  Finally, the
shout for novel therapeutics is
resonating around the earth and
authorities are striving to
answer the cry, making a
healthy hunger for investments in biotech
entities.

This certainly helps explain the
increase in biotech shares world-wide
as possible investing interest is spiking again, including
that in N_u_v_i_l_e_x, Inc. (N-V-L-X), a biotechnology entity
which has shown that their
pancreas can_cer treatment employing its live-cell
encapsulation technology was able to outperform historical
results of Gemzar,  one of the best-selling can_cer
d r u g s ever.  In a Level Two trial,
N u v i le x’s technology was used
to encapsulate cells proficient in activating ifosfamide, a
long-used anti-can_cer d r u g, to its can_cer-killing form,
and then the encapsulated cells were placed in the blo_od
supply near the pancreas, and hence the tumor
itself, in patients with advanced inoperable pancreas can_cer.  After
implantation of the encapsulated cells, ifosfamide was
administered intravenously.  When the
results were matched to historical
figures for Gemzar, N_u_v_i_l_e_x’s treatment ended in a
average survival rate that was twide that
before related for Gemzar
and the one-year survival period was 200 percent
greater!

Even more notable, only one-third of the
typical dose was utilized in the N u v i
le x-treated patients to
produce such strong
results, efficiently
minimizing the severity and
occurrence of side effects that are
classically linked
with chemotherapy.

Adding additional weight to the
potential of N u v i le x, the
organization’s proprietary
live-cell encapsulation technology is an adjustable platform
that reaches far beyond the
compelling information
gener_ated from the pancreas can_cer research.  This
live-cell encapsulation technology, in preclinical studies, has
demonstrated potential as a foundation
on which therapies for a wide assortment
of uses such as can_cers of several
beginnings and other enervating
dis_ease, like dia-betes, may be built.

The movement of countries
worldwide to hold to continue to the time-consuming
and expensive controlling process to bring
new therapies to advertise that has
been intact for decades is hitting a wall.  As a
re_sult, major nations are
evaluating their d-r-u-g approval
procedures and timelines and will possibly bring about
noteworthy changes to
them.  In turn, this brings a sense of
urgency to investors to take a
discriminating look where
significant short-term and long-term
earnings reside in the biotechnology
business.  Judging by
growing biotech investments and
fast earnings; the inquiry
is…Are you passing  the trend?

The use of research materials created by
the auth.or is done at your own risk. You are encouraged to do your own
research before making any investment decision with respect to
the secu rity discussed herein. The author has not been rewarded by any
entity in connection with the disbursement of these
materials. You should assume that as of the date of this report
or letter, the author, possibly along with or through our owners,
affiliates, employees and/or consultants,
(collectively referred to as the author) has a
position in all company shares (and/or options of the shares) covered
herein that is consistent with the position set forth in our report. In
connection with NVLX, the author has taken a long position. Following the
disbursement of any report or letter, the author
plans to continue engaging in trnsactns in the secu rity covered
herein, and we may be long, short, and/or neutral at any time hereafter
regardless of our initial position and we preserve the right to procure or
trade all or part of our position at any time without notice. This practice
could end in our trading securities at any time before, during, and/or
after the disbursement of this report.

 [http://cluster.afrikamangoplus.com/unsubscribe.php?M=6588707&C=0a89a74737fe0ab850bde605efc11be4&L=54&N=146]Remove from list
[http://cluster.afrikamangoplus.com/link.php?M=6588707&N=146&L=8&F=T]
260 Madison Ave., 8th Fl., NY, New York 10016 United States









-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://www.polarhome.com/pipermail/adults/attachments/20130617/ea95be8c/attachment.html>